The EU Home Affairs Sub-Committee has written to Rt Hon Matt Hancock MP, Secretary of State for Health and Social Care, asking for clarity on the Government’s contingency preparations to ensure the UK has continued access to medicines and medical products in the event of a ‘no deal’ Brexit.
The letter follows an evidence session the Sub-Committee held with witnesses from Nuffield Trust, British Association of European Pharmaceutical Distributors and the law firm Maitland Walker LLP on 31 October 2018.
In the letter the Sub-Committee asks the Government what work has been undertaken to ensure the import of medicines and medical products is treated as a priority at the border in the event of no deal. The Sub-Committee also asked:
- How confident are you that the contingency measures deployed as an immediate response to secure the supply of medicines and medical products can be sustained beyond the first six weeks after Brexit, should this be required?
- Can you provide more detail on the tender for additional storage capacity, including: the amount of funding awarded; the size of the storage obtained; and how much of that is for refrigerated storage?
- What plans has the Government made to secure and prioritise airborne routes for medical products?
- What are the Government’s plans to encourage drug companies to prioritise introducing new products to market in the UK?